The Pacific Northwest (PNW) Prostate Cancer SPORE continuation grant represents a coordinated effort of four institutions with established programs and strengths in translational prostate cancer research including basic, clinical, and population sciences as well as career development: 1) the Fred Hutchinson Cancer Research Center (FHCRC);2) the University of Washington (UW) and its affiliated institutions;3) the University of British Columbia and the Prostate Centre of Vancouver General Hospital (UBC);and 4) Oregon Health and Science University (OHSU). These Seattle-, British Columbia- and Portland-based institutions have large multidisciplinary teams of investigators and laboratories dedicated to prostate cancer research and a history of working closely together within this larger milieu. The respective teams of clinicians and researchers at these institutions bring considerable scientific depth, breadth, creativity, and vision required for confronting the most challenging problems blocking progress in our ultimate goal of reducing the morbidity and mortality associated with prostate cancer. This SPORE proposal enlarges the blueprint for a well-built, distinctive and coordinated translational prostate cancer research effort spanning the entire PNW. All participating institutions have made substantial commitments toward supporting the SPORE and its innovative, translational projects: 1) Molecular predictors of prostate cancer progression and mortality;2) Targeting LSD1 in prostate cancer;3) Targeting SEMA3C in castration resistant prostate cancer;4) Clinical development of therapeutic strategies targeting damage responses in the prostate tumor microenvironment;and 5) Exploiting mechanisms of response and resistance to next generation androgen pathway antagonists. We also propose four Cores to support these projects: 1) Leadership and administration;2) Biospecimens;3) Biostatistics;and 4) Clinical research. In addition, we propose a Developmental Research Program and a Career Development Program that will significantly embellish and strengthen the translational goals of our prostate cancer research program and expand opportunities for engaging young as well as established investigators in our multidisciplinary environment.
Prostate cancer (PC) is a major cause of cancer incidence and mortality in US men. This year alone 240,890 men will be diagnosed and 33,720 will die of the disease;and the annual number of men dying from PC is increasing. This highlights the urgent need for translational PC research to uncover the underlying genetic and genomic factors and pathways that drive PC toward its lethal phenotype, including resistance to therapy.
|Kuo, Kevin F; Hunter-Merrill, Rachel; Gulati, Roman et al. (2015) Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer 13:6-Oct|
|Lam, Hung-Ming; Vessella, Robert L; Morrissey, Colm (2014) The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. Drug Discov Today Technol 11:41-7|
|True, Lawrence D (2014) Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice. Virchows Arch 464:257-63|
|Sprenger, Cynthia C T; Plymate, Stephen R (2014) The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer 5:207-17|
|Montgomery, Bruce; Cheng, Heather H; Drechsler, James et al. (2014) Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl 16:354-8|
|O'Hurley, Gillian; Prencipe, Maria; Lundon, Dara et al. (2014) The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate 74:306-13|
|Tarnow, Carolin; Engels, Géraldine; Arendt, Annika et al. (2014) TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol 88:4744-51|
|Barnett, Christine M; Heinrich, Michael C; Lim, Jeong et al. (2014) Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res 20:1306-12|
|Mostaghel, Elahe A; Plymate, Stephen R; Montgomery, Bruce (2014) Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res 20:791-8|
|Chéry, Lisly; Lam, Hung-Ming; Coleman, Ilsa et al. (2014) Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5:9939-51|
Showing the most recent 10 out of 227 publications